- ▲ Trump signed an executive order to accelerate regulatory review of psychedelic treatments, triggering a sharp rally across NASDAQ-listed biopharma names.
- ▲ Compass Pathways led the sector with a 42.3% gain, while AtaiBeckley and GH Research also posted double-digit advances on the day.
- ■ Policy support does not equal immediate product approvals — clinical outcomes and regulatory timelines still determine the pace of commercial development.
Psychedelic drug developers surged Monday after President Donald Trump backed faster regulatory action for mental health treatments, giving fresh momentum to a small group of NASDAQ-listed healthcare names tied to LSD and related therapies. The move followed an executive order aimed at speeding the regulatory process for psychedelic treatments, a development that quickly lifted sentiment across the sector.
Why did psychedelic stocks jump so sharply?
The strongest move came from Compass Pathways, which closed up 42.3%. AtaiBeckley gained 22.2%, GH Research rose 16.9%, and Definium Therapeutics added 2.4%. All four stocks were still trading above their regular-session closes in after-hours trading on Monday, April 20, 2026.
The companies are all listed on the Nasdaq and operate in healthcare or biopharma segments connected to psychedelic research. Investors appeared to treat the policy signal as a potential catalyst for a faster path through clinical development and regulatory review, even though no immediate product approvals were announced.
MarketWatch reported that the policy support came through an executive order intended to accelerate the regulatory process for psychedelic treatments targeting mental illnesses. The primary report is available via MarketWatch.
What could the policy change mean for mental health drug makers?
For these companies, the market reaction reflects expectations rather than confirmed regulatory outcomes. Psychedelic therapies have drawn growing attention for conditions such as depression, trauma-related disorders, and other mental health challenges, but the sector remains dependent on clinical trial data, regulator engagement, and commercial execution.
Monday’s rally suggests investors see political support as a meaningful shift in the backdrop for the industry. Even so, the scale and timing of any benefit will likely depend on how regulators interpret and implement the order, and whether individual drug candidates continue to meet safety and efficacy standards in ongoing studies.
Bybit 20% Fee Discount
Free Coinbix Premium Channel
Market impact stays focused on a niche healthcare trade
The gains were concentrated in a narrow group of psychedelic-focused stocks rather than across the broader pharmaceutical sector. That pattern points to a headline-driven move centered on companies with the most direct exposure to psychedelic treatment themes.
For now, traders are likely to watch whether follow-through buying continues beyond the first policy reaction. They will also be looking for company-specific updates on trial pipelines, partnerships, and any formal signals from regulators that could confirm the market’s initial optimism.
Although the immediate impact was limited to healthcare equities, the rally highlights how policy announcements can quickly reshape sentiment in smaller, thematic corners of the market.
Bybit 20% Fee Discount
Free Coinbix Premium Channel
What happens next?
The next phase will depend on whether Monday’s headline can develop into a clearer regulatory roadmap. Until then, the sector appears to be trading on the possibility that policy support could shorten timelines for psychiatric treatment innovation, while investors wait for more concrete milestones.
Related coverage: Brent Oil Tops $100 After US-Iran Talks Collapse | Bitcoin, Ethereum & Solana: Price Predictions 4/20
Affiliate Disclosure: This page contains affiliate links. Coinbix may earn a commission at no extra cost to you.
Disclaimer: This article is for informational purposes only and does not constitute financial advice. Cryptocurrency investments carry significant risk. Always conduct your own research before making investment decisions.
